[1]田博文 龚凤英 谭惠文.新型减重药物氯卡色林的疗效与安全性的研究进展[J].国际内分泌代谢杂志,2020,40(02):100-103.[doi:10.3760/cma.j.issn.1673-4157.2020.02.007]
　Tian Bowen,Gong Fengying,Tan Huiwen.Research progress on the efficacy and safety of a new weight-loss drug lorcaserin[J].International Journal of Endocrinology and Metabolism,2020,40(02):100-103.[doi:10.3760/cma.j.issn.1673-4157.2020.02.007]
点击复制

新型减重药物氯卡色林的疗效与安全性的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年02期
页码:
100-103
栏目:
综述
出版日期:
2020-03-20

文章信息/Info

Title:
Research progress on the efficacy and safety of a new weight-loss drug lorcaserin
作者:
田博文1 龚凤英2 谭惠文3
1四川大学华西临床医学院,成都 610041; 2中国医学科学院,北京协和医学院,北京协和医院内分泌科,国家卫生健康委员会内分泌重点实验室,协和转化医学中心 100730; 3四川大学华西医院内分泌代谢科,成都 610041
Author(s):
Tian Bowen1;  Gong Fengying2;  Tan Huiwen3
1West China School of Medicine, Sichuan University, Chengdu 610041, China; 2Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, The Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; 3Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China
关键词:
肥胖;  氯卡色林;  有效性;  安全性
Keywords:
Obesity;  Lorcaserin;  Effectiveness;  Safety
DOI:
10.3760/cma.j.issn.1673-4157.2020.02.007
摘要:
肥胖及其并发症对健康和寿命的影响巨大,因此减重药物的研发始终是内分泌领域的热点。氯卡色林(lorcaserin)是2012年获美国FDA批准上市的新型减重药物。它是高度选择性的5-羟色胺2C受体激动剂,通过激动下丘脑抑制食欲的阿片-促黑素细胞皮质素原神经元,抑制食欲,减少能量摄入,进而达到减重的目的。氯卡色林除治疗肥胖之外,对肥胖引起的2型糖尿病、肾功能不全等也具有一定的改善作用。另外,氯卡色林在临床应用中耐受性良好,不良反应程度较轻、发生率较低,对心血管系统的安全性也已经得到证实。因此,氯卡色林与饮食调节、体育锻炼相结合,可以有效地提高患者的减重效果。
Abstract:
Obesity and its complications have a tremendous impact on health and longevity, so the research of weight-loss drugs has always been a hot topic in the field of endocrinology and metabolism.Lorcaserin is a new weight-loss drug approved by FDA in 2012. Lorcaserin is a highly selective serotonin 2C receptor agonist which can decrease energy intake by reducing the appetite in the way of acting on the hypothalamic opioid-melanocyte cortisone neurons. Lorcaserin is also effective in the treatment of obesity and obesity-related disorders such as type 2 diabetes mellitus and renal insufficiency. In addition, lorcaserin is well tolerated in clinical application with mild adverse reactions and low incidence, and its safety for cardiovascular system has been proved. Therefore, the use of lorcaserin combined with dietary restriction and physical exercise can effectively improve the effect of weight loss in obese patients.

参考文献/References:

[1] Kelly T,Yang W,Chen CS,et al.Global burden of obesity in 2005 and projections to 2030[J].Int J Obes(Lond),2008,32(9):1431-1437. DOI:10.1038/ijo.2008.102.
[2] Ng M,Fleming T,Robinson M,et al.Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013:a systematic analysis for the Global Burden of Disease Study 2013[J].Lancet,2014,384(9945):766-781.DOI:10.1016/S0140-6736(14)60460-8.
[3] Jensen MD,Ryan DH,Apovian CM,et al.2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society[J].J Am Coll Cardiol,2014,63(25 Pt B):2985-3023.DOI:10.1016/j.jacc.2013.11.004.
[4] Sumithran P,Prendergast LA,Delbridge E,et al.Long-term persistence of hormonal adaptations to weight loss[J].N Engl J Med,2011,365(17):1597-1604.DOI:10.1056/NEJMoa1105816.
[5] Yanovski SZ,Yanovski JA.Long-term drug treatment for obesity: a systematic and clinical review[J].JAMA,2014,311(1):74-86.DOI:10.1001/jama.2013.281361.
[6] Patel D.Pharmacotherapy for the management of obesity[J].Metabolism,2015,64(11):1376-1385.DOI:10.1016/j.metabol.2015.08.001.
[7] Filip M,Bader M.Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system[J].Pharmacol Rep,2009,61(5):761-777.DOI:10.1016/s1734-1140(09)70132-x.
[8] Bai B,Wang Y.The use of lorcaserin in the management of obesity: a critical appraisal[J].Drug Des Devel Ther,2010,5:1-7.DOI:10.2147/DDDT.S11945.
[9] Smith SR,Weissman NJ,Anderson CM,et al. Multicenter, placebo-controlled trial of lorcaserin for weight management[J].N Engl J Med,2010,363(3):245-256.DOI:10.1056/NEJMoa0909809.
[10] Fidler MC,Sanchez M,Raether B,et al.A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial[J].J Clin Endocrinol Metab,2011,96(10):3067-3077.DOI:10.1210/jc.2011-1256.
[11] O'Neil PM,Smith SR,Weissman NJ,et al.Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus:the BLOOM-DM study[J].Obesity(Silver Spring),2012,20(7):1426-1436.DOI:10.1038/oby.2012.66.
[12] Fujioka K,Malhotra M,Perdomo C,et al.Effect of lorcaserin in different age groups:a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studies[J].Obes Sci Pract,2019,5(2):120-129.DOI:10.1002/osp4.335.
[13] Burke LK,Ogunnowo-Bada E,Georgescu T,et al.Lorcaserin improves glycemic control via a melanocortin neurocircuit[J].Mol Metab,2017,6(10):1092-1102.DOI:10.1016/j.molmet.2017.07.004.
[14] Scirica BM,Bohula EA,Dwyer JP,et al.Lorcaserin and renal outcomes in obese and overweight patients in the CAMELLIA-TIMI 61 trial[J].Circulation,2019,139(3):366-375.DOI:10.1161/CIRCULATIONAHA.118.038341.
[15] Nigro SC,Luon D,Baker WL.Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity[J].Curr Med Res Opin,2013,29(7):839-848.DOI:10.1185/03007995.2013.794776.
[16] Weissman NJ,Sanchez M,Koch GG,et al.Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials[J].Circ Cardiovasc Imaging,2013,6(4):560-567.DOI:10.1161/CIRCIMAGING.112.000128.
[17] Bohula EA,Scirica BM,Fanola C,et al.Design and rationale for the cardiovascular and metabolic effects of lorcaserin in overweight and obese patients-thrombolysis in myocardial infarction 61(CAMELLIA-TIMI 61)trial[J].Am Heart J,2018,202:39-48.DOI:10.1016/j.ahj.2018.03.012.
[18] Bohula EA,Wiviott SD,McGuire DK,et al.Cardiovascular safety of lorcaserin in overweight or obese patients[J].Send to N Engl J Med,2018,379(12):1107-1117.DOI:10.1056/NEJMoa1808721.
[19] Tuccinardi D,Farr OM,Upadhyay J,et al.Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults:a six-month, randomized, placebo-controlled, double-blind clinical trial[J]. Diabetes Obes Metab,2019,21(6):1487-1492.DOI:10.1111/dom.13655.
[20] Shukla AP,Kumar RB,Aronne LJ.Lorcaserin Hcl for the treatment of obesity[J].Expert Opin Pharmacother,2015,16(16):2531-2538.DOI:10.1517/14656566.2015.1096345.

相似文献/References:

[1]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
　Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(02):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[2]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
　Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(02):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[3]胡明玥 沈山梅.棕色脂肪检测技术的研究进展[J].国际内分泌代谢杂志,2015,(01):41.[doi:10.3760/cma.j.issn.1673-4157.2015.01.010]
　Hu Mingyue*,Shen Shanmei..Assessments of brown adipose tissue Hu Mingyue*,Shen Shanmei.*Medical College of Southeast University,Nanjing 210009,China[J].International Journal of Endocrinology and Metabolism,2015,(02):41.[doi:10.3760/cma.j.issn.1673-4157.2015.01.010]
[4]郑仁东,曹琳,刘克冕,等.超重或肥胖的男性2型糖尿病患者 性激素水平的研究[J].国际内分泌代谢杂志,2015,(02):84.[doi:10.3760/cma.j.issn.1673-4157.2015.02.004]
　Zheng Rendong,Cao Lin,Liu Kemian,et al.Study on sex hormone levels in overweight or obese type 2 diabetic male patients[J].International Journal of Endocrinology and Metabolism,2015,(02):84.[doi:10.3760/cma.j.issn.1673-4157.2015.02.004]
[5]王滢,李倩.脑利钠肽与糖脂代谢的关系[J].国际内分泌代谢杂志,2015,(02):103.[doi:10.3760/cma.j.issn.1673-4157.2015.02.008]
　Wang Ying,Li Qian..Association between brain natriuretic peptide and glycolipid metabolism[J].International Journal of Endocrinology and Metabolism,2015,(02):103.[doi:10.3760/cma.j.issn.1673-4157.2015.02.008]
[6]王兴纯,程晓芸,曲伸.代餐饮食对代谢紊乱改善的作用及其机制[J].国际内分泌代谢杂志,2015,(02):106.[doi:10.3760/cma.j.issn.1673-4157.2015.02.009]
　Wang Xingchun,Cheng Xiaoyun,Qu Shen..Roles of meal replacement in the improvement of metabolic disorders and related mechanism[J].International Journal of Endocrinology and Metabolism,2015,(02):106.[doi:10.3760/cma.j.issn.1673-4157.2015.02.009]
[7]贺肴,张弛,刘瑛,等.代谢正常肥胖合并非酒精性脂肪性肝病的临床特征及内皮功能研究[J].国际内分泌代谢杂志,2015,(03):163.[doi:10.3760/cma.j.issn.1673-4157.2015.03.005]
　He Yao,Zhang Chi,Liu Ying,et al.Clinical features and endothelial function in metabolically healthy obese patients with nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2015,(02):163.[doi:10.3760/cma.j.issn.1673-4157.2015.03.005]
[8]黄莉吉,谢绍锋,刘超.肥胖相关性肾病的研究进展[J].国际内分泌代谢杂志,2015,(03):180.[doi:10.3760/cma.j.issn.1673-4157.2015.03.010]
　Huang Liji*,Xie Shaofeng,Liu Chao..Obesity-related glomerulopathy[J].International Journal of Endocrinology and Metabolism,2015,(02):180.[doi:10.3760/cma.j.issn.1673-4157.2015.03.010]
[9]刘美娟,朱惠娟,龚凤英.Glypican-，4与肥胖及胰岛素抵抗[J].国际内分泌代谢杂志,2015,(03):183.[doi:10.3760/cma.j.issn.1673-4157.2015.03.011]
　Liu Meijuan,Zhu Huijuan,Gong Fengying..Glypican-4 and obesity，insulin resistance[J].International Journal of Endocrinology and Metabolism,2015,(02):183.[doi:10.3760/cma.j.issn.1673-4157.2015.03.011]
[10]刘琳,高鑫.肥胖与心脏结构及功能的改变[J].国际内分泌代谢杂志,2015,(03):187.[doi:10.3760/cma.j.issn.1673-4157.2015.03.012]
　Liu Lin,Gao Xin..Relationship between obesity and changes of cardiac structure and function[J].International Journal of Endocrinology and Metabolism,2015,(02):187.[doi:10.3760/cma.j.issn.1673-4157.2015.03.012]

备注/Memo

备注/Memo:
通信作者:谭惠文:Email:huiwent2016@scu.edu.cn
基金项目:四川省科技厅科技支撑计划项目(2016SZ0058)
Corresponding author: Tian Huiwen, Email:huiwent2016@scu.edu.cn
Fund program:Science and Technology Support Program Foundation of Sichuan Science and Technology Department(2016SZ0058)
更新日期/Last Update: 2020-03-20